<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022825</url>
  </required_header>
  <id_info>
    <org_study_id>CA-ALT-803-01-16</org_study_id>
    <nct_id>NCT03022825</nct_id>
  </id_info>
  <brief_title>QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</brief_title>
  <official_title>QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altor BioScience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altor BioScience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, open-label, single-arm, multicenter study of intravesical BCG plus
      ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer
      (NMIBC). All patients treated in the study will receive via a urinary catheter in the
      bladder, BCG plus ALT-803 weekly for 6 consecutive weeks (initial induction treatment
      period). After the first disease assessment, eligible patients will receive either a 3-week
      maintenance course or a 6-week re-induction course (second treatment period) at Month 3.
      Eligible patients will continue to receive maintenance treatment in the third treatment
      period at Months 6, 9, 12, and 18. The study duration is 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2017</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>24 Months</time_frame>
    <description>Cohort A &amp; Cohort C: Assess incidence of complete response of CIS (with or without Ta/T1 papillary disease) patients at any time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-Free Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Cohort B: Assess disease-free rate at 12 months since first study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>24 months</time_frame>
    <description>Cohort A &amp; Cohort C: Assess duration of complete response Cohort B: Assess disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>6 months</time_frame>
    <description>Cohort A &amp; Cohort C: Assess complete response rate at 6 months. Cohort B: Assess disease-free rate at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>9 months</time_frame>
    <description>Cohort A &amp; Cohort C: Assess complete response rate at 9 months. Cohort B: Assess disease-free rate at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>12 months</time_frame>
    <description>Cohort A &amp; Cohort C: Assess complete response rate at 12 months. Cohort B: Assess disease-free rate at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>18 months</time_frame>
    <description>Cohort A &amp; Cohort C: Assess complete response rate at 18 months. Cohort B: Assess disease-free rate at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>24 months</time_frame>
    <description>Cohort A &amp; Cohort C: Assess complete response rate at 24 months. Cohort B: Assess disease-free rate at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>24 months</time_frame>
    <description>Assess complete response rate at any time of CIS patients per central pathology review Duration of complete response (all recurrent bladder cancer, including low grade Ta disease)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>BCG+ALT-803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-803 and BCG</intervention_name>
    <description>BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18.</description>
    <arm_group_label>BCG+ALT-803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>ALT-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18.</description>
    <arm_group_label>BCG+ALT-803</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years of age or older

          -  Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell
             carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell
             histology is predominant histology).

          -  Histologically confirmed presence of BCG-unresponsive CIS (with or without Ta or T1
             disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1
             disease.

          -  Absence of resectable disease after transurethral resection (TURBT) procedures
             (residual carcinoma in situ (CIS) acceptable; patients with T1 tumors must undergo
             repeat resection and biopsy [inclusive of muscularis propria] if initial biopsy did
             not include muscularis propria). Patients with high-grade Ta and/or T1 disease should
             have complete resection before study treatment.

          -  BCG-unresponsive disease as defined as: (a) Persistent or recurrent CIS (+/- recurrent
             Ta/T1 disease) within 12 months of receiving adequate BCG (at least five of six doses
             doses of an initial induction course plus either at least two of three doses of
             maintenance therapy or at least two of six doses of a second induction course); or (b)
             Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG (at
             least five of six doses of an initial induction course plus either at least two of
             three doses of maintenance therapy or at least two of six doses of a second induction
             course); or (c) T1 high-grade disease at the first evaluation following an induction
             BCG course alone (at least five of six doses of an initial induction course).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Voluntary written informed consent and HIPAA authorization and agree to comply with
             all protocol-specified procedures and follow-up evaluations

        Exclusion Criteria:

          -  Recurrence of BCG unresponsive Ta/T1 disease (without presence of CIS) &gt; 6 months
             after last BCG instillation or BCG unresponsive CIS &gt; 12 months after last BCG
             instillation.

          -  Life expectancy &lt;2 years

          -  Any of the following clinical laboratory values at the time of enrollment: (1)
             Absolute neutrophil count (ANC) &lt;800/µL or (2) Platelets &lt; 50,000/µL

          -  Liver function abnormalities as indicated by ongoing hepatic enzyme elevation (AST or
             ALT) &gt;2 times upper limit of normal (ULN)

          -  Renal insufficiency as indicated by a creatinine level &gt;3 times ULN

          -  History of or evidence of muscle-invasive, locally advanced, metastatic and/or
             extravesical bladder cancer; or any other cancer within the past 5 years, except:
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
             adequately treated stage I or II cancer from which the patient is currently in
             complete remission, or stable prostate cancer (under active surveillance or hormone
             control).

          -  Symptomatic congestive heart failure (CHF), New York Heart Association (NYHA) Class
             III or IV heart failure or other clinical signs of severe cardiac dysfunction

          -  Severe/unstable angina pectoris, or myocardial infarction within 6 months prior to
             study entry

          -  History or evidence of uncontrollable central nervous system (CNS) disease

          -  Active systemic infection requiring parenteral antibiotic therapy. All prior
             infections must have resolved following optimal therapy

          -  Concurrent febrile illness, active urinary tract infection, active tuberculosis, a
             history of hypotension or anaphylactic reactions

          -  Ongoing chronic systemic steroid therapy required (&gt;10 mg oral prednisone daily or
             equivalent)

          -  Women who are pregnant or nursing. Female patients of childbearing potential must have
             a negative pregnancy test and must adhere to using a medically acceptable method of
             birth control prior to screening and agree to continue its use during the study and
             for 30 days after the last dose of study drug, or be surgically sterilized (e.g.,
             hysterectomy or tubal ligation). Women of childbearing potential are defined as any
             female who has experienced menarche and who is NOT permanently sterile or
             postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses
             without an alternative medical cause. Males must agree to use barrier methods of birth
             control while on study and for 90 days post last dose of study drug.

          -  Patients currently receiving investigational or commercial anti-cancer agents or
             anti-cancer therapies other than BCG, ALT-803 and supportive care therapies for active
             disease.

          -  Concurrent use of other investigational agents

          -  Other illness or condition, including laboratory abnormalities, which in the opinion
             of the Investigator would exclude the patient from participating in this study. This
             includes, but is not limited to, serious medical conditions or psychiatric illness
             likely to interfere with participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Chamie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Rock, PhD</last_name>
    <phone>954-443-8600</phone>
    <email>Amy.Rock@Immunitybio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liza Hernandez-Ochoa, BS</last_name>
    <phone>954-443-8600</phone>
    <email>Liza.HOchoa@ImmunityBio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alaska Clinical Research Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Morris</last_name>
      <phone>907-276-1455</phone>
      <email>PMorris@akmed.com</email>
    </contact>
    <investigator>
      <last_name>William R Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie O'Brien</last_name>
      <phone>501-219-8900</phone>
      <phone_ext>2002</phone_ext>
      <email>katie@arkansasurology.com</email>
    </contact>
    <investigator>
      <last_name>Richard D'Anna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Coast Urology</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UCLA Department of Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ankush Sachdeva</last_name>
      <phone>310-794-3421</phone>
      <email>ASachdeva@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Karim Chamie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Associates, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lenden Neeper, MS</last_name>
      <phone>303-733-8848</phone>
      <phone_ext>1262</phone_ext>
      <email>L.Neeper@uradenver.com</email>
    </contact>
    <investigator>
      <last_name>Barrett Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rody Barakat</last_name>
      <phone>305-243-2177</phone>
      <email>rxb773@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Mark L Gonzalgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Austin Lannon</last_name>
      <phone>813-745-2169</phone>
      <email>Austin.Lannon@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Wade J Sexton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dwight D. Eisenhower Army Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Salazar</last_name>
      <phone>706-787-5811</phone>
      <email>elsa.c.salazar2.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Aaron Brothers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makenzie Svihrama</last_name>
      <phone>734-232-0798</phone>
      <email>svihrama@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel D Kaffenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Dimovski</last_name>
      <phone>313-576-9771</phone>
      <email>dimovskt@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Michael L Cher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Urology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Bowles, RN</last_name>
      <phone>402-399-7823</phone>
      <email>kbowles@adultpediatricuro.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Trainer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accument Rx</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Showen</last_name>
      <phone>505-872-4091</phone>
      <phone_ext>107</phone_ext>
      <email>eshowen@accumentrx.com</email>
    </contact>
    <investigator>
      <last_name>Fred Snoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Insitute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sreejeta Dasgupta</last_name>
      <phone>716-845-8730</phone>
      <email>Sreejeta.Dasgupta@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Khurshid Guru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital Department of Urology</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Palmer, PhD</last_name>
      <phone>516-535-4187</phone>
      <email>Mary.Palmer@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Aaron E Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmela Graci-Pipitone, RN</last_name>
      <phone>212-480-3333</phone>
      <email>cgpipitone@manhattanmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jed Kaminetsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Gray, RN</last_name>
      <phone>845-437-3804</phone>
      <email>Lgray@premiermedicalhv.com</email>
    </contact>
    <investigator>
      <last_name>Evan Goldfischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene D Doyle, LPN</last_name>
      <phone>585-275-0126</phone>
      <email>dee_doyle@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Edward Messing, MD</last_name>
      <phone>585-275-0126</phone>
    </contact_backup>
    <investigator>
      <last_name>Edward Messing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Paterno, RN</last_name>
      <phone>919-537-3505</phone>
      <email>christopher_paterno@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Hung-Jui Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiplyne Moffett</last_name>
      <phone>919-758-7386</phone>
      <email>kmoffett@auncurology.com</email>
    </contact>
    <investigator>
      <last_name>Mark W Jalkut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Burns</last_name>
      <phone>215-503-3754</phone>
      <email>Katherine.Burns@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Edouard Trabulsi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Steele, RN</last_name>
      <phone>615-343-2120</phone>
      <email>pamela.steele@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Sam Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Rose</last_name>
      <phone>804-288-2785</phone>
      <email>clrose@uro.com</email>
    </contact>
    <investigator>
      <last_name>Eugene Kramolowsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Thomas</last_name>
      <phone>253-968-2300</phone>
      <email>drew.m.thomas2.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Timothy C Brand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCG</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>interleukin-15</keyword>
  <keyword>intravesical</keyword>
  <keyword>non-muscle invasive</keyword>
  <keyword>NMIBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

